X T L Biopharmaceuticals Ltd

XTLB

1.060USD

+0.050+4.95%

Market hours （ET）Quotes delayed by 15 min

X T L Biopharmaceuticals Ltd's Score

Industry at a Glance

Industry Ranking

240 / 407

Overall Ranking

481 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

--

Current Rating

--

Target Price

--

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

X T L Biopharmaceuticals Ltd Highlights

StrengthsRisks

XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Growing

The company is in a growing phase, with the latest annual income totaling USD 451.00K.

Fairly Valued

The company’s latest PE is -6.60, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 237.40K shares, decreasing 7.88% quarter-over-quarter.

The company's current financial score is 4.49, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

4.49

Change

0



Financials

4.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.81

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 7.47, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.60, which is -100.00% below the recent high of 0.00 and -631.08% above the recent low of -48.26.

Score

Industry at a Glance

Previous score

7.47

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 240/407

No Data

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.10, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 2.06 and the support level at 0.48, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.59

Change

-0.49

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Rabinovitch (Alexander)

1.46M

+120.96%

Klinger (Roy)

862.29K

--

Klinger (Tal)

862.29K

--

Yaacobi (Yaron)

450.00K

--

Noked Capital Ltd.

198.89K

--

Rhumbline Advisers Ltd. Partnership

17.26K

+57.58%

Morgan Stanley & Co. LLC

11.01K

-16.90%

Geode Capital Management, L.L.C.

8.90K

--

Turgeman (Doron)

3.40K

--

UBS Financial Services, Inc.

1.34K

--



1

2



The company’s current risk assessment score is 1.41, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

X T L Biopharmaceuticals Ltd

XTLB

3.90 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment